28.09.2022 07:25:00

Dow Jones Newswires: Eisai shares indicated sharply higher after trial of experimental drug slows Alzheimer’s progression

Eisai and Biogen BIIB said Wednesday that their drug, lecanemab, reduced cognitive and functional decline by 27%, compared with a placebo, over 18 months in a Phase 3 study of 1,800 patients with early-stage Alzheimer's.
Weiter zum vollständigen Artikel bei "MarketWatch"